Skip to main content
SpringerLink
Log in

Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma

  • Chapter
Current Controversies in Bone Marrow Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

  • 97 Accesses

Abstract

Mantle cell lymphoma (MCL) is a unique subtype of non-Hodgkin’s lymphoma (NHL). In the past, this lymphoma was classified (or misclassified) as diffuse smallcleaved-cell lymphoma or follicular small-cleaved-cell lymphoma, in the International Working Formulation (1–3); as centrocytic lymphoma, in the Kiel classification (4); as lymphocytic lymphoma of intermediate differentiation (5); as intermediate cell lymphoma (5); or as mantle zone lymphoma (6). The term “mantle cell lymphoma” was proposed in 1992 (7) and was defined by the Revised European-American Lymphoma Classification in 1994 (8). MCL has a distinct morphology, histology, and immunophenotype (CDS+, CD19+, CD20+, CD10−, CD23−), which are now widely accepted, and increasingly recognized This lymphoma and subset of patients is more specifically defined by a distinct translocation, t(11;14)(q13;32), which results in the rearrangement of the bcl-1 locus, and overexpression of cyclin D1 protein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, and Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study, Blood, 85 (1995) 1075–1082.

    PubMed  CAS  Google Scholar 

  2. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’ s lymphoma subtypes, J. Clin. Oncol., 13 (1995) 2819–2826.

    PubMed  CAS  Google Scholar 

  3. Pittaluga S, Bignens L, Teodorovic I, et al. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation, Blood, 87 (1996) 4385–4367.

    Google Scholar 

  4. Lennert K, Mohri N, Stein H, et al. The histopathology of maligiant lymphoma, Br. J. Haematol., 31 (Suppl) (1975) 193–203.

    Google Scholar 

  5. Beard CW and Dorfman RF. Histopathology of malignant lymphoma. In Rosenberg SA (ed), Clinics in Hematology, WB Saunders, London, 3 (1974) 39.

    Google Scholar 

  6. Weisenburger DD, Nathwani BN, Diamond LW, Winberg CD, and Rappaport H. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases, Cancer, 48 (1981) 1415–1425.

    Article  PubMed  CAS  Google Scholar 

  7. Banks PM, Chan J, Clear ML, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data, Am. J. Surg. Pathol., 16 (1992) 637–640.

    Article  PubMed  CAS  Google Scholar 

  8. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group, Blood, 84 (1994) 1361–1392.

    PubMed  CAS  Google Scholar 

  9. Armitage JO, Weisenburger DD, for the Non-Hodgkin’ s Lymphoma Classification Project. New approach to classifying non-Hodgkin’s lymphomas: clinical features for the major histologic subtypes, J. Clin. Oncol., 16 (1998) 2780–2740.

    PubMed  CAS  Google Scholar 

  10. Press OW, Grogan TM, and Fisher RI. Evaluation and management of mantle cell lymphoma, Adv. Leukemia Lymphoma., 6 (1996) 3–11.

    Google Scholar 

  11. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis, Hematol. Oncol., 7 (1989) 365–380.

    Article  PubMed  CAS  Google Scholar 

  12. Stewart DA, Vose JM, Weisenburger DD, et al. Role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma, Ann. Oncol., 6 (1995) 263–266.

    PubMed  CAS  Google Scholar 

  13. Haas R, Brittinger G, Neusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma, Leukemia, 10 (1996) 975–979.

    Google Scholar 

  14. Dreger P, von Neuhoff N, Kuse R, et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma, Ann. Oncol., 8 (1997) 401–403.

    Article  PubMed  CAS  Google Scholar 

  15. Gressin R, Legouffe E, Leroux D, et al. Treatment of mantle-cell lymphomas with the VAD +/chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation, Ann. Oncol.,8 (Suppl. 1) (1997) 103–106.

    Google Scholar 

  16. Ketterer N, Salles G, Espinouse D, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma, Ann. Oncol., 8 (1997) 701–704.

    Article  PubMed  CAS  Google Scholar 

  17. Khouri I, Romaguera J, Kantarjian H, et al. Preliminary report of an active regimen for mantle cell lymphoma, Blood,90 (Suppl. 1) (1997) 1092(Abstract).

    Google Scholar 

  18. Romaguera J, Khouri J, Hagemeister FB, et al. HCVAD/Ara-C-MTX with or without high-dose chemotherapy and stem cell transfusion as salvage for relapsed or refractory diffuse/nodular mantle cell lymphoma, Blood,90 (Suppl. 1) (1997) 834(Abstract).

    Google Scholar 

  19. Blay JY, Sebban C, Surbiguet C, et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients, Bone Marrow Transplant., 21 (1998) 51–54.

    Article  PubMed  CAS  Google Scholar 

  20. Conde E, Bosch F, Arranz R, et al. Autologous stem cell transplantation for mantle cell lymphoma. The experience of the GEL/TAMO Spanish Cooperative Group, Blood,92 (Suppl. 1) (1998) 1915(Abstract).

    Google Scholar 

  21. Freedman AS, Neuberg D, Gribben JG, et al. High-Dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission, J. Clin. Oncol., 16 (1998) 13–18.

    PubMed  CAS  Google Scholar 

  22. Khouri I, Korbling M, Albitar M, et al. Allogeneic stem cell transplantation for mantle cell lymphoma (MCL): evidence of graft-versus-lymphoma effect (GVL), Blood,90 (Suppl. 1) (1998) 2708(Abstract).

    Google Scholar 

  23. Kröger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy, Bone Marrow Transplant., 21 (1998) 55–57.

    Article  PubMed  Google Scholar 

  24. Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience, Bone Marrow Transplant., 22 (1998) 645–650.

    Article  PubMed  CAS  Google Scholar 

  25. Molina A, Nademanee A, O’Donnell MR, et al. Autologous (auto) and allogeneic (allo) stem cell transplantation (SCT) for poor-risk mantle cell lymphoma (MCL): the City of Hope (COH) experience, Blood,92 (suppl 1) (1998) 1894(Abstract).

    Google Scholar 

  26. Sohn SK, Bensinger W, Holmberg L, et al. High-dose therapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: the Seattle experience, Proc. ASCO.,17 (1998) 64(Abstract).

    Google Scholar 

  27. Suzan F, Belanger C, Ribrag V, et al. Preliminary report of a strategy assessing a CHOP-regimen and high dose ara-C (DHAP) followed by high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) for mantle cell lymphoma (MCL), Blood,92 (Suppl. 1) (1998) 1916(Abstract).

    Google Scholar 

  28. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin’ s lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting, Blood, 89 (1997) 724–731.

    PubMed  CAS  Google Scholar 

  29. Jacquy C, Soree A, Bosly A, Ferrant A, Bron D, and Martiat P. Peripheral blood stem cells contamination in diffuse large cell (DLCL) and mantle cell (MCL) lymphomas: a quantitative comparison, Blood,92 (Suppl. 1) (1998) 976(Abstract).

    Google Scholar 

  30. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease, Blood,90 (1997) 42124221.

    Google Scholar 

  31. Uehira K, Kagami Y, Ogura M, et al. A high dose chemoradiotherapy and peripheral blood stem cell support combined with the CD34(+)-selection method in cyclin D1(+)-mantle cell lymphoma, Int. J. Hematol., 67 (1998) 187–190.

    Article  PubMed  CAS  Google Scholar 

  32. Di Nicola M, Magni M, Milanesi M, et al. Successful elimination of follicular or mantle non-Hodgkin lymphoma cells from hematopoietic progenitor cell transplants by high-dose chemotherapy and ex-vivo purging of CD19+ cells, Blood,92 (Suppl. 1) (1998) 2677(Abstract).

    Google Scholar 

  33. Romaguera J, Khouri I, Champlin R, et al. HCVAD/MTX-ARAC: A new effective regimen for diffuse and nodular mantle cell lymphoma (MCL), Blood,88 (Suppl. 1) (1996) 2261(Abstract).

    Google Scholar 

  34. Tongol JM, Carrum G, Udden MM, Lynch G, Williams G, McCarthy PL. Successful allogeneic transplantation in a patient with mantle cell lymphoma, Proc. ASCO.,14 (1995) 11(Abstract).

    Google Scholar 

  35. Adkins D, Brown R, Goodnough LT, Khoury H, Popovic W, and DiPersio J. Treatment of resistant mantle cell lymphoma with allogeneic. Bone marrow transplantation, Bone Marrow Transplant., 21 (1998) 97–99.

    Google Scholar 

  36. Corradini P, Ladetto M, Astolfi M, et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma, Br. J. Haematol., 94 (1996) 376–378.

    Article  PubMed  CAS  Google Scholar 

  37. Copelan E, Penza S, Pohlman B, et al. A novel Bu/CyNP-16 regimen in non-Hodgkin’s lymphoma, Blood,92 (Suppl. 1) (1998) 2737(Abstract).

    Google Scholar 

Download references

Authors
  1. Brad Pohlman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Brian J. Bolwell MD (Director, Staff Physician) (Director, Staff Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Pohlman, B. (2000). Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-657-7_11

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9812-7

  • Online ISBN: 978-1-59259-657-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation